BFM
BMY.RT

Boothbay Fund Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Boothbay Fund Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-512,322
Closed -$354K – 2012
2020
Q4 		$354K Buy
512,322
+124,979
+32% +$266K 0.01% 885
2020
Q3 		$872K Buy
387,343
+183,985
+90% +$525K 0.05% 475
2020
Q2 		$728K Sell
203,358
-14,827
-7% -$53.5K 0.05% 472
2020
Q1 		$829K Buy
218,185
+89,878
+70% +$296K 0.07% 343
2019
Q4 		$386K Buy
+128,307
New +$334K 0.03% 552

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Boothbay Fund Management's BMY.RT Position: Q1 2021 in Review

Boothbay Fund Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 512,322 shares — an estimated $354K sold.

Boothbay Fund Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $872K in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Boothbay Fund Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 512,322 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $354K.
  • Boothbay Fund Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Boothbay Fund Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $872K in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Boothbay Fund Management's 13F filing for Q1 2021, filed 17 May 2021.